Status of biological agent therapy in inflammatory bowel disease.
- Author:
Jia-ming QIAN
1
;
Hao TANG
Author Information
1. Department of Gastroenterology, Chinese Academy of Medical Science, Beijing, China. qjiaming1957@yahoo.cn
- Publication Type:Journal Article
- MeSH:
Biological Products;
adverse effects;
therapeutic use;
Humans;
Inflammatory Bowel Diseases;
drug therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2013;16(4):311-314
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of conventional drug therapy for inflammatory bowel disease (IBD) is not satisfactory. As monoclonal antibody has been widely used and increasingly understood, biological agent therapy has been proved as ideal strategy in attaining mucosal healing, preventing complications, improving quality of life, and reducing hospitalization and surgical intervention. Furthermore, different randomized clinical trials assessed the efficacy in reducing the need for repeat surgery because of recurrence. Besides, biological agent therapy dose not increase most of postoperative side effects such as infection. However, adverse events of biological agents including serious infection, infusion reactions, delay type allergic reaction and myelosuppression should be paid attention to.
